OTLK Stock Analysis: Buy, Sell, or Hold?
OTLK - Outlook Therapeutics, Inc. Common Stock
$0.91
-0.06 (-6.51%)
▼
5d:
-14.27%
30d:
-37.03%
90d:
+248.21%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 13, 2026
8d
Get Alerted When OTLK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: OTLK is down 14.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: OTLK is down 14.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: OTLK is currently trading at $0.91, which is considered oversold relative to its 30-day fair value range of $1.15 to $1.65.
Technical Outlook: Technically, OTLK is in a strong uptrend. Immediate support is located at $0.82, while resistance sits at $1.75. Short-term momentum is weak, with the stock down 6.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.40 (+491.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OTLK is in a strong uptrend. Immediate support is located at $0.82, while resistance sits at $1.75. Short-term momentum is weak, with the stock down 6.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.40 (+491.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.15 -
$1.65
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.5%)
- BULLISH: Trading 491.5% below Wall St target ($5.40)
- WARNING: Recommendation downgraded due to -14.3% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.15 -
$1.65
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.82
Resistance Level
$1.75
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.71
Wall Street Target
$5.40
(+491.5%)
Revenue Growth (YoY)
658.3%
Share & Embed Analysis
Last updated: August 03, 2026 9:39 PM ET
Data refreshes hourly during market hours. Next update: 10:39 PM
Data refreshes hourly during market hours. Next update: 10:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OTLK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 50 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$834 | 58 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$267 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 56 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$33 | 58 HOLD |
